Nanometer trapping agent for thienopyridine antiplatelet drugs and preparation method and application thereof

Through the combination of nanocarriers of nanocapture agents and capture functional groups, the bleeding risk problem caused by antiplatelet drugs is solved, and the effect of antiplatelet drugs is quickly reversed, reducing the risk of bleeding is suitable for the recovery of platelet hemostasis function in emergency situations.

CN118903469APending Publication Date: 2024-11-08UNIV OF CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411130483.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing antiplatelet drugs, such as clopidogrel and pragrarel, cause bleeding risks that are difficult to reverse, especially when it is necessary to quickly restore platelet hemostasis in emergencies. The lack of effective reversal drugs leads to high risk of bleeding and recurrence. Risk of sexual thrombosis events.

Method used

Developed a nanocapture agent, including nanocarriers and capture functional groups modified on the surface of the carrier, can quickly react to capture antiplatelet drugs or their metabolites, reduce blood drug concentration, and restore platelet hemostasis function. The nanocarrier may be selected from silicon groups, lipids, gold, etc., and the capture functional groups may be selected from maleimide, o-phenylquinone, haloacetyl groups, etc., and the action of antiplatelet drugs may be reversed through click chemical reactions or other chemical reactions.

Benefits of technology

It effectively reduces the blood concentration of antiplatelet drugs, restores the physiological hemostasis function of platelets, and reduces the risk of bleeding. It is suitable for reverse application in emergencies, and the preparation method is simple and efficient, with high specificity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903469A_ABST
    Figure CN118903469A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of nano drugs, in particular to a nano trapping agent for thienopyridine antiplatelet drugs as well as a preparation method and application of the nano trapping agent. The nano trapping agent comprises a nano carrier and a trapping functional group modified on the surface or inside the carrier, and can effectively trap active ingredients of various thienopyridine anti-platelet drugs and effectively reverse the anti-platelet function of the thienopyridine anti-platelet drugs. When a patient taking the anti-platelet medicine for a long time has serious bleeding complications or needs to accept emergency surgical operations, the nano trapping agent can rapidly capture active ingredients of the anti-platelet medicine in blood circulation, effectively reduce the blood concentration of the anti-platelet medicine, recover the physiological hemostasis function of platelets and improve the curative effect of the anti-platelet medicine. And the bleeding risk of the cardiovascular patient is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of nano-drugs, and in particular to a nano-capturing agent for thienopyridine antiplatelet drugs, and a preparation method and application thereof. Background Art

[0002] Antiplatelet drugs are the first-line clinical drugs for the treatment and prevention of thrombotic diseases and have been shown to have significant therapeutic effects in reducing the occurrence of ischemic cardiovascular events. Platelet activation and aggregation play a critical role in the pathogenesis of thrombotic diseases. Antiplatelet drugs can inhibit platelet aggregation and thus inhibit intravascular thrombosis. According to the mechanism of action of antiplatelet drugs, the commonly used antiplatelet drugs in clinical practice include (1) thromboxane A2 inhibitors, the representative drug being aspirin; (2) P2Y 12 Receptor inhibitors, representative drugs include clopidogrel, prasugrel, ticagrelor and cangrelor; (3) glycoprotein IIb / IIIa receptor inhibitors, such as tirofiban, abciximab, etc.; (4) phosphodiesterase inhibitors, such as cilostazol, etc.

[0003] Although the use of antiplatelet drugs can significantly reduce the occurrence of ischemic vascular events in patients, the inhibition of platelet function will inevitably affect the body's hemostatic function and produce bleeding side effects. Therefore, patients using antiplatelet drugs face a high risk of bleeding side effects. When patients using antiplatelet drugs encounter the following two emergencies, it is necessary to reverse the antiplatelet effect in their bodies: (i) persistent heavy bleeding caused by the drug itself (such as intracranial hemorrhage, gastrointestinal bleeding, etc.). This clinical emergency may require the rapid reversal of the antiplatelet drugs in the body on the basis of standard measures to effectively restore normal hemostatic function to achieve successful hemostasis; (ii) emergency surgery and traumatic bleeding, immediate drug withdrawal is usually not enough to quickly restore the body's hemostatic function. Therefore, it is very necessary to develop antidotes that can immediately reverse platelet inhibitors.

[0004] In clinical practice, P2Y 12Inhibitors have the highest clinical usage rate, and clopidogrel has become the first choice of antiplatelet drugs due to its relatively good tolerability, with the highest market share. Clopidogrel and prasugrel are both irreversible antiplatelet drugs. Through liver metabolism, their metabolites can irreversibly bind to platelets to exert their functions. The inhibitory effect of clopidogrel or prasugrel on platelets can last for several days after discontinuation of the drug, thereby increasing the risk of perioperative bleeding. Current clinical guidelines recommend that in patients undergoing elective coronary artery bypass surgery, clopidogrel should be discontinued at least 5 days in advance and prasugrel at least 7 days in advance to restore platelet hemostatic function and avoid excessive bleeding. Because this approach may put patients at high risk of recurrent thrombotic events, it is particularly important to efficiently reverse the antiplatelet function of clopidogrel or prasugrel and restore platelet hemostatic activity when patients experience life-threatening bleeding episodes. Normally, platelet transfusion is chosen clinically to alleviate the bleeding risk of patients taking antiplatelet drugs. However, since the transfusion dosage is difficult to control, excessive platelet transfusion will bring thrombosis risk to patients, so its clinical use effect is still controversial. In addition, there is currently no dedicated reversal drug for clopidogrel or prasugrel available. The development of specific clopidogrel or prasugrel antiplatelet function reversal agents has important research value and clinical medical value.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] In order to solve the above technical problems, the present invention provides a nano-capture agent for thienopyridine antiplatelet drugs and a preparation method and application thereof.

[0007] Specifically, the technical solution of the present invention is as follows: In a first aspect, the present invention provides a nano-capture agent, comprising a nano-carrier and a capture functional group modified inside or on the surface of the nano-carrier, wherein the capture functional group can undergo a rapid chemical reaction with a thienopyridine antiplatelet drug or its active metabolite to capture the antiplatelet drug or its metabolite.

[0008] Preferably, the nanocarrier is selected from any one or a combination of at least two of silicon-based nanocarriers, lipid nanoparticles, gold nanoparticles, polymer nanocarriers, metal and oxide nanocarriers, metal-organic framework carriers, polypeptide nanoparticles, DNA / RNA nanocarriers, nanohydrogels, and carbon-based nanocarriers.

[0009] Preferably, the capture functional group is selected from any one of maleimide, o-benzoquinone, halogenated acetyl, and pyridine dithiol, or a combination of at least two thereof; wherein the halogenated acetyl group may be iodoacetamide or chloroacetamide.

[0010] Preferably, the antiplatelet drug is one or more of clopidogrel, prasugrel and ticlopidine.

[0011] More preferably, the nanocarrier is mesoporous silicon nanoparticles, liposome nanoparticles, gold nanoparticles or polymer nanoparticles; more preferably, it is mesoporous silicon nanoparticles.

[0012] More preferably, the capture functional group is maleimide, o-benzoquinone or haloacetyl; more preferably maleimide.

[0013] More preferably, the antiplatelet drug is selected from clopidogrel and prasugrel.

[0014] Further preferably, the nano-capturing agent is a nanoparticle modified with a capturing group (such as mesoporous silicon nanoparticles modified with maleimide); its particle size is 1-5000nm, preferably 1-500nm, more preferably 10-200nm; its surface Zeta potential is -50mV to +50mV, preferably -50mV to +10mV.

[0015] In a second aspect, the present invention provides two methods for preparing the nano-capturing agent.

[0016] Method 1 comprises the following steps: (1) preparing a nanocarrier; (2) modifying a capture group on the surface or inside of the nanocarrier; and (3) collecting the nanocapture agent by centrifugation.

[0017] Method 2 comprises the following steps: (1) preparing a precursor molecule modified with a capture group; (2) preparing the precursor molecule to form nanoparticles; and (3) collecting the nano-capture agent by centrifugation.

[0018] When the nano-capturing agent of the present invention is a mesoporous silica capturing agent, firstly, silica nano-carrier particles with a mesoporous structure are prepared, and then the silane coupling agent modified with the capturing functional group is fixed into the mesoporous structure of the nano-carrier particles.

[0019] Preferably, the silane coupling agent is silane polyethylene glycol maleimide Silane-PEG-MAL.

[0020] In another preferred embodiment, the silane coupling agent is silane polyethylene glycol o-benzoquinone Silane-PEG-BQ.

[0021] In another preferred embodiment, the silane coupling agent is silane polyethylene glycol iodoacetamide Silane-PEG-IA.

[0022] In the present invention, the molecular weight of the polyethylene glycol in the silane coupling agent is preferably 400-20000; more preferably 600, 800 or 1000.

[0023] In a more specific embodiment provided by the present invention, the preparation method of the nano-capturing agent comprises the following steps: (1) preparing mesoporous silicon nanoparticles; (2) modifying a silane coupling agent modified with a maleimide group, an o-benzoquinone group, or a haloacetyl group into the mesopores of the mesoporous silicon nanoparticles; and (3) collecting the nano-capturing agent by centrifugation.

[0024] Wherein, the centrifugal speed is preferably 2000-20000g.

[0025] In a third aspect, the present invention provides the use of the nano-capture agent or the preparation method in reversing the pharmacodynamic function of thienopyridine antiplatelet drugs or preventing bleeding caused by antiplatelet drugs.

[0026] In a fourth aspect, the present invention provides the use of the nano-capture agent or the preparation method in the preparation of a nano-drug having the function of reversing the efficacy of thienopyridine antiplatelet drugs or preventing bleeding caused by antiplatelet drugs.

[0027] Beneficial effects: The present invention provides a nano-capturing agent for thienopyridine antiplatelet drugs, and a preparation method and application thereof. The nano-capturing agent of the present invention comprises a nano-carrier and a capturing functional group modified on the surface or inside of the carrier, which can effectively capture a variety of thienopyridine antiplatelet drugs and effectively reverse their antiplatelet function. When patients who take such antiplatelet drugs for a long time develop severe bleeding complications or need to undergo emergency surgery, the nano-capturing agent of the present invention can quickly capture the active ingredients of the antiplatelet drugs in the blood circulation, effectively reduce the blood concentration of the antiplatelet drugs, restore the physiological hemostatic function of platelets, and thus reduce the bleeding risk of cardiovascular patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the drawings required for use in the embodiments or the description of the prior art will be described below.

[0029] Figure 1 It is a schematic diagram of the structure of the nano-capture agent of the present invention consuming the active metabolites of thienopyridine antiplatelet drugs.

[0030] Figure 2 These are transmission electron micrographs of the SiO2-Mal nano-capturing agent prepared in Example 1 ((A) SiO2-Mal (600), (B) SiO2-Mal (800), (C) SiO2-Mal (1000)), with the scale bar being 100 nm.

[0031] Figure 3This is the particle size distribution diagram of the SiO2-Mal nanotrap prepared in Example 1 measured by dynamic light scattering ((A) SiO2-Mal (600), (B) SiO2-Mal (800), (C) SiO2-Mal (1000)).

[0032] Figure 4 TEM images of different SiO2 nano-capture agents prepared in Examples 2 and 3 ((A) SiO2-BQ and (B) SiO2-IA), with a scale of 50 nm.

[0033] Figure 5 Graphs showing particle size distributions of different SiO2 nanotraps prepared in Examples 2 and 3 measured by dynamic light scattering ((A) SiO2-BQ and (B) SiO2-IA).

[0034] Figure 6 This is a transmission electron microscopy image of the Lipo-Mal nanotrap prepared in Example 4, with a scale of 200 nm.

[0035] Figure 7 This is the particle size distribution diagram of the Lipo-Mal nanotrap prepared in Example 4 measured by dynamic light scattering.

[0036] Figure 8 This is a transmission electron microscopy image of the AuNPs-PEG-Mal nanotrap prepared in Example 5, with a scale of 50 nm.

[0037] Fig. 9 This is the particle size distribution diagram of the AuNPs-PEG-Mal nanotrap prepared in Example 5 measured by dynamic light scattering.

[0038] Fig.10 This is a transmission electron microscopy image of the PLGA-PEG-Mal nano-capturing agent prepared in Example 6, with a scale of 200 nm.

[0039] Fig.11 This is the particle size distribution diagram of the PLGA-PEG-Mal nanotrap prepared in Example 6 measured by dynamic light scattering.

[0040] Fig.12 This is a graph showing the results of the SiO2-Mal nano-trap in Example 1 acting on the platelet aggregation rate of each group of clopidogrel antiplatelet drug active ingredient.

[0041] Fig.13 This is a graph showing the results of the SiO2-Mal nano-trap in Example 1 acting on the platelet aggregation rate of each group of prasugrel antiplatelet drug active ingredients.

[0042] Fig.14This is a graph showing the results of the tail tip bleeding time of mice treated with the antiplatelet drug clopidogrel under the action of the SiO2-Mal nano-traps (SiO2-Mal (600), SiO2-Mal (800), SiO2-Mal (1000)) in Example 1.

[0043] Fig.15 This is a graph showing the results of the tail tip bleeding time of mice treated with the antiplatelet drug prasugrel under the action of the SiO2-Mal nano-traps (SiO2-Mal (600), SiO2-Mal (800), SiO2-Mal (1000)) in Example 1.

[0044] Fig.16 The graphs show the results of the amount of liver bleeding (A) and bleeding time (B) of the SiO2-Mal nano-traps (SiO2-Mal (600), SiO2-Mal (800), SiO2-Mal (1000)) in Example 1 acting on the antiplatelet drug clopidogrel in mice.

[0045] Fig.17 The graphs show the results of the SiO2-Mal nano-traps (SiO2-Mal (600), SiO2-Mal (800), SiO2-Mal (1000)) in Example 1 on the liver bleeding weight (A) and bleeding time (B) of mice treated with the antiplatelet drug prasugrel.

[0046] Fig.18 The graphs show the results of (A) SiO2-BQ and (B) SiO2-IA nanotraps in Examples 2 and 3 on the tail tip bleeding time of mice administrated with clopidogrel antiplatelet drug.

[0047] Fig.19 These are the results of the tail tip bleeding time of mice treated with the antiplatelet drug prasugrel by (A) SiO2-BQ and (B) SiO2-IA nanotraps in Examples 2 and 3.

[0048] Fig. 20 The graphs are the result of the SiO2-BQ nanotrap of Example 2 acting on the mouse liver bleeding amount (A) and bleeding time (B) of the antiplatelet drug clopidogrel, and the graphs are the result of the SiO2-IA nanotrap of Example 3 acting on the mouse liver bleeding amount (C) and bleeding time (D) of the antiplatelet drug clopidogrel.

[0049] Fig.21 This is a graph showing the results of the Lipo-Mal nanotrap in Example 4 acting on the platelet aggregation rates of each group of clopidogrel antiplatelet drug active ingredients.

[0050] Fig. 22This is a graph showing the results of the tail tip bleeding time of mice treated with clopidogrel antiplatelet drug as a result of the Lipo-Mal nanotrap in Example 4.

[0051] Fig.23 This is a graph showing the results of the AuNPs-PEG-Mal nanotrap in Example 5 acting on the platelet aggregation rates of each group of clopidogrel antiplatelet drug active ingredients.

[0052] Fig.24 This is a graph showing the results of the AuNPs-PEG-Mal nanotrap in Example 5 acting on the tail tip bleeding time of mice taking the antiplatelet drug clopidogrel.

[0053] Fig.25 This is a graph showing the results of the platelet aggregation rate of each group of clopidogrel antiplatelet drug active ingredient as a result of the PLGA-PEG-Mal nanotrap in Example 6 acting on the platelet aggregation rate of each group.

[0054] Fig.26 This is a graph showing the result of the tail tip bleeding time of mice treated with clopidogrel antiplatelet drug as measured by the PLGA-PEG-Mal nanotrap in Example 6.

[0055] Fig. 27 This is the H&E staining image of the main organs obtained after the SiO2-Mal nanotrap in Example 1 was injected into the mouse. DETAILED DESCRIPTION

[0056] Targeting existing platelet surface P2Y 12 The invention provides a nano-capturing agent and its preparation method and application to reduce the risk of bleeding caused by the receptor inhibitors clopidogrel, prasugrel and ticlopidine. The nano-capturing agent can be used to reverse the bleeding risk of antiplatelet drugs or to stop bleeding in patients taking antiplatelet drugs.

[0057] Firstly, the present invention provides a nano-capturing agent.

[0058] In the present invention, the nano-capturing agent comprises a nano-carrier and a capturing functional group modified on its surface or inside. The capturing functional group is a functional group that can react rapidly with a thiol group under mild conditions. The nano-capturing agent captures antiplatelet drugs or their active metabolites, reduces their blood drug concentration, promotes the recovery of platelet aggregation function, and reverses the function of antiplatelet drugs.

[0059] In the present invention, the nanoparticle carrier includes any one or a combination of at least two of silicon-based nanoparticles such as mesoporous silica nanoparticles, lipid nanoparticles, gold nanoparticles, polymer nanoparticles, metal and oxide nanomaterials, metal-organic framework materials, quantum dots, polypeptide nanoparticles, DNA / RNA nanostructures, nanohydrogels, carbon-based nanomaterials, etc. Preferably, the nanoparticle carrier is mesoporous silica, liposomes, gold nanoparticles, and polymer nanoparticles.

[0060] In the present invention, the particle size of the nano-capturing agent can be selected to be 1-5000nm, such as 50nm, 100nm, 150nm, 200nm, 250nm, 300nm, 500nm, 1000nm, 2000nm, 5000nm, etc., and other specific point values ​​within this numerical range can be selected. Preferably, it is 1-500nm, and more preferably, it is 10-200nm.

[0061] In the present invention, the surface potential (Zeta potential) of the nanotrap reversal agent is about +50 mV to about -50 mV, preferably about +10 mV to about -50 mV.

[0062] In the present invention, the modified capture functional group includes maleimide, o-benzoquinone, haloacetyl (iodoacetamide, chloroacetamide, etc.), pyridine dithiol, etc. Preferably, the modified functional group is maleimide.

[0063] In the present invention, the antiplatelet drug is a P2Y 12 Receptors, drugs that inhibit platelet activation and aggregation and prevent thrombosis.

[0064] In the present invention, the antiplatelet drug may be an antiplatelet drug that has been marketed, or a drug that has been marketed and has indications other than thrombotic diseases but has the above-mentioned properties, or a substance that has not been marketed but has the potential for the above-mentioned pharmacological properties.

[0065] In the present invention, the antiplatelet drug is a thienopyridine antiplatelet drug with clear pharmacological activity, including but not limited to: clopidogrel, prasugrel, and ticlopidine.

[0066] Furthermore, the present invention provides a method for preparing the nano-capturing agent.

[0067] In the present invention, the preparation method includes but is not limited to: After the nanoparticles are dispersed uniformly by ultrasound, the functional groups to be modified are added and mixed uniformly, and the functional groups to be modified are modified by chemical reaction using the characteristic functional groups on the surface or inside of the nanoparticles, including maleimide, o-benzoquinone, halogenated acetyl (iodoacetamide, chloroacetamide, etc.), pyridine dithiol, etc. The nano-capturing agent obtained after the reaction is then collected by centrifugation; or the characteristic functional groups are directly loaded into the initial polymer or other materials for preparing the nanoparticles, and the nano-capturing agent loaded with the characteristic functional groups is directly prepared by synthesizing the nanoparticles.

[0068] The nano-capturing agent involved in the present invention adopts a chemical modification method to obtain the required characteristic functional groups. Different chemical reactions can be selected according to the characteristics of the surface functional groups of different nanoparticles or the characteristics of the preparation raw materials. The preparation method is simple and efficient, the raw materials are easily available, the yield is high and the application range is wide. It is suitable for both laboratory research and application and industrial production.

[0069] The nano-capturing agent of the present invention has good biocompatibility and basically does not induce hemolytic reaction, heart damage, liver damage, spleen damage, lung damage or kidney damage.

[0070] Furthermore, the present invention also provides the application of the nano-capturing agent or the preparation method. For example, the nano-capturing agent of the present invention is applied as a reversal agent of antiplatelet drugs.

[0071] The present invention utilizes nano-capture agents to reverse the effect of antiplatelet drugs, and uses materials such as porous silicon nano-silicon particles as carriers. The drug needs to enter the pores and then react with the capture group, which can improve the accuracy of the capture group binding to the target and avoid interference caused by other components in the blood that are similar to the drug structure. Compared with the prior art, the nano-capture agent involved in the present invention can quickly capture free antiplatelet drugs or their active metabolites in the circulation, that is, capture and consume active metabolites through click chemistry reactions or other chemical reactions, reduce the drug concentration in the circulation, and reverse the antiplatelet effect. It is suitable for patients who take antiplatelet drugs for a long time to reduce the risk of bleeding when serious bleeding complications occur or emergency pioneering operations are required. In addition, the preparation method of the nano-capture agent involved in the present invention also has the advantages of being simple and efficient, high specificity, and high yield.

[0072] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in combination with the embodiments and drawings. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0073] The endpoints and any values ​​of the ranges disclosed in this specification are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0074] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "specific implementations", or "some specific implementations" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the embodiment of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0075] In the examples provided in this specification, if no specific techniques or conditions are specified, the techniques or conditions described in the literature in this field or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased through regular channels.

[0076] The present invention provides a nanotrap, the mechanism of action of reversing antiplatelet function is as follows Figure 1 The modified capture functional groups in the nanotrap include maleimide, vinyl sulfone and other double-bonded functional groups that can undergo click chemistry reactions with thiol groups, or iodoacetamide, chloroacetamide, iodoacetic acid and o-benzoquinone and other functional groups that can undergo alkylation reactions with thiol groups, and functional groups that can form disulfide bonds with thiol groups. The above functional groups can react with the active metabolites of thienopyridine antiplatelet drugs, and then capture and consume the active metabolites, thereby reducing the drug concentration in the circulating blood, promoting platelet aggregation, and reversing the antiplatelet effect.

[0077] Example 1

[0078] This embodiment provides a SiO2-Mal nanotrap, and the preparation method is as follows: Mesoporous silica nanoparticles were prepared by sol-gel method, that is, cationic surfactant CTAC was used as template, TEOS was used as silicon source, TEA was used as catalyst, 1-octadecene and other organic solvents were used as emulsifier, and a one-pot two-phase layered method was used for continuous growth to obtain 3D dendritic mesoporous silica with central-radial mesoporous channels, and then the template was removed. The obtained mesoporous silica was uniformly dispersed in toluene solution, and then a silane coupling agent (molecular weight of 600, 800, 1000) connected to maleimide group was added, stirred for 24 h, and then centrifuged at 12000 r / min for 20 min, and mesoporous silica nanotraps were obtained after washing with ethanol and water.

[0079] like Figure 2 The following are transmission electron micrographs of the prepared SiO2-Mal nanotraps, namely SiO2-Mal (600), SiO2-Mal (800) and SiO2-Mal (1000). Figure 3 As shown, the average hydrated particle size of SiO2-Mal (600) nanotrap was measured by a laser particle size analyzer (Zetasizer Nano ZS90, Malvern, UK) to be 173.4 nm, with a dispersion of 0.219 and a zeta potential of -33.9 mV; the average hydrated particle size of SiO2-Mal (800) nanotrap was measured to be 179.3 nm, with a dispersion of 0.223 and a zeta potential of -33.1 mV; the average hydrated particle size of SiO2-Mal (1000) nanotrap was measured to be 184.6 nm, with a dispersion of 0.198 and a zeta potential of -34.1 mV.

[0080] Example 2

[0081] This embodiment provides a SiO2-BQ nanotrap, and the preparation method is as follows: Mesoporous silica nanoparticles were prepared by sol-gel method, that is, cationic surfactant CTAC was used as template, TEOS was used as silicon source, TEA was used as catalyst, 1-octadecene and other organic solvents were used as emulsifier, and a one-pot two-phase layered method was used for continuous growth to obtain 3D dendritic mesoporous silica with central-radial mesoporous channels, and then the template was removed. The obtained mesoporous silica was uniformly dispersed in toluene solution, and then a silane coupling agent connected to o-benzoquinone group was added, stirred for 24 h, and then centrifuged at 12000 r / min for 20 min, and mesoporous silica nanotraps were obtained after washing with ethanol and water.

[0082] like Figure 4 Figure A shows a transmission electron microscope image of the prepared SiO2-BQ nanotrap. Figure 5As shown in Figure A, the average hydrated particle size of the SiO2-Mal nanotrap measured by a laser particle size analyzer (Zetasizer Nano ZS90, Malvern, UK) is 186.3 nm, the dispersion is 0.260, and the zeta potential is -32.5 mV.

[0083] Example 3

[0084] This embodiment provides a SiO2-IA nanotrap, and the preparation method is as follows: Mesoporous silica nanoparticles were prepared by sol-gel method, that is, cationic surfactant CTAC was used as template, TEOS was used as silicon source, TEA was used as catalyst, 1-octadecene and other organic solvents were used as emulsifier, and a one-pot two-phase layered method was used for continuous growth to obtain 3D dendritic mesoporous silica with central-radial mesoporous channels, and then the template was removed. The obtained mesoporous silica was uniformly dispersed in toluene solution, and then a silane coupling agent connected with iodoacetamide was added, stirred for 24 h, and then centrifuged at 12000 r / min for 20 min, and mesoporous silica nanotraps were obtained after washing with ethanol and water.

[0085] like Figure 4 Figure B shows a transmission electron microscope image of the prepared SiO2-IA nanotrap. Figure 5 As shown in Figure B, the average hydrated particle size of the SiO2-IA nanotrap measured by a laser particle size analyzer (Zetasizer Nano ZS90, Malvern, UK) was 182.7 nm, the dispersion was 0.211, and the zeta potential was -34.7 mV.

[0086] Example 4

[0087] This embodiment provides a method for preparing maleimide-modified liposomes, and the preparation method is as follows: Phosphatidylcholine, cholesterol and DSPE-PEG (2000) -Mal were dissolved in organic solvents at a molar ratio of 56.5:38.5:5, and the above solutions were mixed and transferred to a round-bottom flask. The solvent was heated by a rotary evaporator and the vacuum was reduced to completely volatilize the organic solvent to form a well-dispersed film. After the phospholipid bilayer film was hydrated for 1 hour, the solution was collected in an EP tube. The solution passed through a polycarbonate membrane with a specific pore size. Large-sized or multi-chamber liposomes were sheared and ruptured by the membrane pores and quickly repolymerized into liposomes with smaller particle sizes. The pore sizes of the polycarbonate membrane were 400nm, 200nm, and 100nm, respectively, and the final particle size was close to the pore size of the polycarbonate membrane 100nm and the distribution was concentrated. Single-chamber liposome Lipo-Mal.

[0088] like Figure 6The figure shows a transmission electron microscope image of the prepared Lipo-Mal nanotrap. Figure 7 As shown, the average particle size of the nanoparticles measured by a laser particle size analyzer (Zetasizer Nano ZS90, Malvern, UK) is 154.83 nm, the dispersion is 0.09, and the zeta potential is -45.76 mV.

[0089] Example 5

[0090] This embodiment provides an AuNPs-PEG-Mal nanotrap, and the preparation method is as follows: The synthesis of AuNPs adopted the classic method of reducing HAuCl4 with citrate in deionized water, namely the Turkevich method. 1.5 mL of sodium citrate solution (3.3% (w / v)) was quickly added to 150 mL of boiling deionized water, and then 1.5 mL of chloroauric acid solution (1% (w / v)) was added under vigorous stirring. After the solution color turned into wine red, it was stirred for 15 minutes, the reaction was stopped, and after cooling, disodium citrate-modified gold nanoparticles of about 15 nm were obtained. The prepared AuNPs were centrifuged (10000 g, 20 minutes) 3 times to remove the unreacted citrate. Then 10 mg of NH2-PEG (5000)-Mal was added to 1 mL of AuNPs (100 nM) stock solution and reacted vigorously at 60 °C for 30 min. Then AuNPs-PEG-Mal was centrifuged at high speed (12,000g) three times to remove the unreacted NH2-PEG (5000)-Mal. The obtained AuNPs-PEG-Mal was redispersed in deionized water and stored at 4 °C.

[0091] like Figure 8 The figure shows the transmission electron micrograph of the prepared AuNPs-PEG-Mal nanotrap. Fig. 9 As shown, the average particle size of AuNPs-PEG-Mal nanoparticles was measured by a laser particle size analyzer (Zetasizer Nano ZS90, Malvern, UK), which was 52.34 nm, the dispersion was 0.38, and the zeta potential was 1.31 mV.

[0092] Example 6

[0093] This embodiment provides a PLGA-PEG-Mal nanotrap, and the preparation method is as follows: Preparation of PLGA-PEG-Mal (poly(lactic-co-glycolic acid) block poly(ethylene glycol)-maleimide) nanoparticles PLGA-PEG-Mal nanoparticles were prepared by a one-step nanoprecipitation technique followed by dialysis. Briefly, 20 mg PLGA-PEG-Mal was dissolved in 1 mL DMSO to form an organic phase. The organic phase was then added dropwise to 30 ml of deionized water with constant stirring to form a colloidal suspension, which was gently stirred for 1 h. Finally, the residual solvent was removed using a dialysis membrane with deionized water, filtered using a 0.22 µm Minisart® syringe filter, and stored in a refrigerator for further use.

[0094] like Fig.10 The figure shows a transmission electron micrograph of the prepared PLGA-PEG-Mal nanotrap. Fig.11 As shown, the average hydrated particle size of the PLGA-PEG-Mal nano-traps was measured by a laser particle size analyzer (Zetasizer Nano ZS90, Malvern, UK) to be 128.6 nm, the dispersion was 0.090, and the zeta potential was -28.3 mV.

[0095] Application Example 1 Platelet Aggregation Experiment

[0096] In this application example, the SiO2-Mal (600) nanotrap prepared in Example 1 was investigated for reversing the antiplatelet effect of clopidogrel in the ADP-induced platelet aggregation model, and the method was as follows: Anticoagulated whole blood (sodium citrate anticoagulation) was collected from SD rats and centrifuged at 130 g for 10 minutes to obtain platelet-rich plasma (PRP). Subsequently, platelet-poor plasma (PPP) was obtained by further centrifugation at 1500 g for 15 minutes. Clopidogrel active metabolite (CLP-AM) at a final concentration of 6 μg / ml or prasugrel active metabolite (PRA-AM) at a final concentration of 4 μg / ml was added to 200 μl PRP and gently mixed. After incubation for 30 minutes, SiO2-Mal (600) nanotraps were added and incubated for another 10 minutes. Subsequently, ADP-induced platelet aggregation rate was measured using a CS2400 fully automated coagulation analyzer.

[0097] The experimental results are as follows Fig.12 and 13 As shown in the figure, the platelet aggregation rate results show that compared with the PBS control group, CLP-AM or PRA-AM can significantly reduce the platelet aggregation rate, and SiO2-Mal (600) nano-traps can significantly increase the platelet aggregation rate inhibited by CLP-AM or PRA-AM. This shows that SiO2-Mal (600) nano-traps can effectively reverse the antiplatelet effect of clopidogrel or prasugrel.

[0098] Application Example 2 Tail tip bleeding time experiment

[0099] In this application example, the SiO2-Mal nanotrap prepared in Example 1 was used to investigate the reversal of the antiplatelet effect of clopidogrel, and the method was as follows: After a single injection of clopidogrel (3 mg / kg) into the tail vein of C57BL-6J mice, the SiO2-Mal nanoparticle group was injected with the nanoparticles of Example 1 (2.5 mg / kg) once, and the control group was injected with the same volume of saline. The saline control group was not injected with clopidogrel, but only with saline. Subsequently, the bleeding time of the tail tip of the mice at different time points was measured, that is, the tail tip of the mice was quickly cut off by about 3 mm with sterile surgical scissors, and the tail was immediately immersed in 37°C saline. The tail tip bleeding time is from the continuous blood line seen in the saline to the blood line stopping and no repeated bleeding within 30 seconds.

[0100] The results are as follows Fig.14 As shown in the figure, after clopidogrel was intravenously injected into C57BL-6J mice, the tail tip bleeding time gradually increased, and the highest tail tip bleeding time appeared at 3 hours, indicating that clopidogrel was gradually converted into clopidogrel active metabolites and exerted antiplatelet effects. The injection of SiO2-Mal nano-traps significantly reduced the tail tip bleeding time caused by clopidogrel. This shows that SiO2-Mal nano-traps have a significant functional reversal effect on the antiplatelet drug clopidogrel.

[0101] Application Example 3 Tail tip bleeding time experiment

[0102] In this application example, the SiO2-Mal nanotrap prepared in Example 1 was used to investigate the reversal of the antiplatelet effect of prasugrel, and the method was as follows: After a single injection of prasugrel (0.3 mg / kg) into the tail vein of C57BL-6J mice, the SiO2-Mal nanoparticle group was injected with the nanoparticles of Example 1 (2.5 mg / kg) once, the CLP control group was injected with the same volume of saline, and the saline control group was not injected with clopidogrel, but only with saline. Subsequently, the bleeding time of the tail tip of the mice at different time points was measured, that is, the tail tip of the mice was quickly cut off by about 3 mm with sterile surgical scissors, and the tail was immediately immersed in 37°C saline. The tail tip bleeding time is from the continuous blood line seen in the saline to the blood line stopping and no repeated bleeding within 30 seconds.

[0103] The results are as follows Fig.15As shown in the figure, after prasugrel was intravenously injected into C57BL-6J mice, the tail tip bleeding time gradually increased, and the highest tail tip bleeding time appeared at 3 hours, indicating that prasugrel was gradually converted into active metabolites and exerted antiplatelet effects. The injection of SiO2-Mal nanotraps significantly reduced the tail tip bleeding time caused by prasugrel. This shows that SiO2-Mal nanotraps have a significant functional reversal effect on the antiplatelet drug prasugrel.

[0104] Application Example 4 Liver Bleeding Experiment

[0105] In the liver injury model, C57BL / 6J mice were randomly divided into a saline group, a clopidogrel (CLP) group, and a CLP + SiO2-Mal nanotrap group. Mice in the CLP group and CLP + SiO2-Mal group were intravenously injected with clopidogrel 3 mg / kg. Mice in the CLP + SiO2-Mal group were intravenously injected with SiO2-Mal nanotrap (2.5 mg / kg), and mice in the CLP group were injected with an equal amount of saline. Mice were anesthetized with 1.25% tribromoethanol solution and fixed on a surgical board. Then, the abdomen was shaved and wiped with iodine. Subsequently, an abdominal incision was made to expose the liver, and the surrounding serous fluid was carefully drained. A pre-weighed filter paper was placed under the liver, and one of the liver lobes was injured with a 2 mm diameter punch. The bleeding time and amount were recorded until the bleeding stopped.

[0106] The results are as follows Fig.16 As shown, after clopidogrel was intravenously injected into C57BL-6J mice, the bleeding time and amount of liver bleeding increased, indicating that clopidogrel exerted an antiplatelet effect. The use of SiO2-Mal nanotraps significantly reduced the increase in bleeding time and amount caused by clopidogrel. This indicates that SiO2-Mal nanotraps have a significant functional reversal effect on the antiplatelet drug clopidogrel.

[0107] Application Example 5 Liver Bleeding Experiment

[0108] In the liver injury model, C57BL / 6J mice were randomly divided into saline group, prasugrel (PRA) group and PRA + SiO2-Mal nanotrap group. PRA group and PRA + SiO2-Mal group mice were intravenously injected with prasugrel 0.3 mg / kg. PRA + SiO2-Mal group mice were intravenously injected with SiO2-Mal nanotrap (2.5 mg / kg), and PRA group mice were injected with an equal amount of saline. Mice were anesthetized with 1.25% tribromoethanol solution and fixed on the surgical board. Then, the abdomen was shaved and wiped with iodine. Subsequently, the abdominal incision was made to expose the liver, and the surrounding serous fluid was carefully drained. A pre-weighed filter paper was placed under the liver, and one of the liver lobes was injured with a 2 mm diameter punch. The bleeding time and amount were recorded until the bleeding stopped.

[0109] The results are as follows Fig.17 As shown, after prasugrel was intravenously injected into C57BL-6J mice, the bleeding time and amount of liver bleeding increased, indicating that prasugrel exerted an antiplatelet effect. The use of SiO2-Mal nanotraps significantly reduced the increase in bleeding time and bleeding amount caused by prasugrel. This indicates that SiO2-Mal nanotraps have a significant functional reversal effect on the antiplatelet drug prasugrel.

[0110] Application Example 6 Tail tip bleeding time experiment

[0111] In this application example, the SiO2-BQ or SiO2-IA nanotrap prepared in Example 2 or 3 is investigated to reverse the antiplatelet effect of clopidogrel, and the method is as follows: After a single injection of clopidogrel (3 mg / kg) into the tail vein of C57BL-6J mice, the SiO2-BQ or SiO2-IA nanoparticle group was injected once (2.5 mg / kg), the CLP control group was injected with the same volume of saline, and the saline control group was not injected with clopidogrel, but only with saline. Subsequently, the bleeding time of the tail tip of the mice at different time points was measured, that is, the tail tip of the mouse was quickly cut off about 3 mm with sterile surgical scissors, and the tail was immediately immersed in 37°C saline. The tail tip bleeding time is from the continuous blood line seen in the saline to the blood line stopping and no repeated bleeding within 30 seconds.

[0112] The results are as follows Fig.18As shown in the figure, after clopidogrel was intravenously injected into C57BL-6J mice, the tail tip bleeding time gradually increased, and the highest tail tip bleeding time appeared at 3 hours, indicating that clopidogrel was gradually converted into clopidogrel active metabolites and exerted antiplatelet effects. The injection of SiO2-BQ or SiO2-IA nanotraps significantly reduced the tail tip bleeding time caused by clopidogrel. This indicates that SiO2-BQ or SiO2-IA nanotraps have a significant functional reversal effect on the antiplatelet drug clopidogrel.

[0113] Application Example 7 Tail tip bleeding time experiment

[0114] In this application example, the SiO2-BQ or SiO2-IA nanotrap prepared in Example 2 or 3 was used to investigate the reversal of the antiplatelet effect of prasugrel, and the method was as follows: After a single injection of prasugrel (0.3 mg / kg) into the tail vein of C57BL-6J mice, the SiO2-BQ or SiO2-IA nanoparticle group was injected once (2.5 mg / kg), the PRA control group was injected with the same volume of saline, and the saline control group was not injected with prasugrel, but only with saline. Subsequently, the bleeding time of the tail tip of the mice at different time points was measured, that is, the tail tip of the mouse was quickly cut off about 3 mm with sterile surgical scissors, and the tail was immediately immersed in 37°C saline. The tail tip bleeding time is from the continuous blood line seen in the saline to the blood line stopping and no repeated bleeding within 30 seconds.

[0115] The results are as follows Fig.19 As shown in the figure, after prasugrel was intravenously injected into C57BL-6J mice, the tail tip bleeding time gradually increased, and the highest tail tip bleeding time appeared at 3 hours, indicating that prasugrel was gradually converted into prasugrel active metabolites and exerted antiplatelet effects. The injection of SiO2-BQ or SiO2-IA nanotraps significantly reduced the tail tip bleeding time caused by prasugrel. This indicates that SiO2-BQ or SiO2-IA nanotraps have a significant functional reversal effect on the antiplatelet drug prasugrel.

[0116] Application Example 8 Liver Bleeding Experiment

[0117] In the liver injury model, C57BL / 6J mice were randomly divided into normal saline group, clopidogrel (CLP) group and CLP + SiO2-BQ or SiO2-IA nanotrap group. Mice in the CLP group and CLP + SiO2-BQ or SiO2-IA nanotrap group were intravenously injected with clopidogrel 3 mg / kg. Mice in the CLP + SiO2-BQ or SiO2-IA nanotrap group were intravenously injected with SiO2-BQ or SiO2-IA nanotrap (2.5 mg / kg), and mice in the CLP group were injected with an equal amount of normal saline. Mice were anesthetized with 1.25% tribromoethanol solution and fixed on a surgical board. Then, the abdomen was shaved and wiped with iodine. Subsequently, the abdominal incision was made to expose the liver, and the surrounding serous fluid was carefully drained. A pre-weighed filter paper was placed under the liver, and one of the liver lobes was injured with a 2 mm diameter punch. The bleeding time and amount were recorded until the bleeding stopped.

[0118] The results are as follows Fig. 20 As shown, after clopidogrel was intravenously injected into C57BL-6J mice, the hepatic bleeding time and bleeding volume increased, indicating that clopidogrel exerted an antiplatelet effect. The use of SiO2-BQ or SiO2-IA nanotraps significantly reduced the increase in bleeding time and bleeding volume caused by clopidogrel. This indicates that SiO2-BQ or SiO2-IA nanotraps have a significant functional reversal effect on the antiplatelet drug clopidogrel.

[0119] Application Example 9 Platelet Aggregation Experiment

[0120] In this application example, the Lipo-Mal nanotrap prepared in Example 4 was investigated for reversing the antiplatelet effect of clopidogrel in the ADP-induced platelet aggregation model, and the method was as follows: Anticoagulated whole blood (sodium citrate anticoagulation) was collected from SD rats and centrifuged at 130 g for 10 minutes to obtain platelet-rich plasma (PRP). Platelet-poor plasma (PPP) was obtained by further centrifugation at 1500 g for 15 minutes. CLP-AM at a final concentration of 6 μg / ml was added to 200 μl PRP and gently mixed. After incubation for 30 minutes, Lipo-Mal nanotraps were added and incubated for another 10 minutes. Subsequently, the ADP-induced platelet aggregation rate was measured using a CS2400 fully automated coagulation analyzer.

[0121] The experimental results are as follows Fig.21 As shown in the figure, the platelet aggregation rate results show that compared with the blank control group, CLP-AM can significantly reduce the platelet aggregation rate, and Lipo-Mal nano-traps can significantly increase the platelet aggregation rate inhibited by CLP-AM. This shows that Lipo-Mal nano-traps can effectively reverse the antiplatelet effect of clopidogrel.

[0122] Application Example 10 Tail tip bleeding time experiment

[0123] In this application example, the Lipo-Mal nanotrap prepared in Example 4 was used to investigate the reversal of the antiplatelet effect of clopidogrel, and the method was as follows: After a single injection of clopidogrel (3 mg / kg) into the tail vein of C57BL-6J mice, the Lipo-Mal nanoparticle group was injected with the Lipo-Mal nanoparticles (2.5 mg / kg) of Example 4, the CLP control group was injected with the same volume of saline, and the blank control group was not injected with clopidogrel, but only with saline. Subsequently, the bleeding time of the tail tip of the mice at different time points was measured, that is, the tail tip of the mice was quickly cut off by about 3 mm with sterile surgical scissors, and the tail was immediately immersed in 37°C saline. The tail tip bleeding time is from the continuous blood line seen in the saline to the blood line stopping and no repeated bleeding within 30 seconds.

[0124] The results are as follows Fig. 22 As shown in the figure, after clopidogrel was intravenously injected into C57BL-6J mice, the tail tip bleeding time gradually increased, and the highest tail tip bleeding time appeared at 3 hours, indicating that clopidogrel was gradually converted into clopidogrel active metabolites and exerted antiplatelet effects. The injection of Lipo-Mal nano-traps significantly reduced the tail tip bleeding time caused by clopidogrel. This shows that Lipo-Mal nano-traps have a significant functional reversal effect on the antiplatelet drug clopidogrel.

[0125] Application Example 11 Platelet Aggregation Experiment

[0126] In this application example, the AuNPs-PEG-Mal nanotrap prepared in Example 5 was investigated for reversing the antiplatelet effect of clopidogrel in the ADP-induced platelet aggregation model, and the method was as follows: Anticoagulated whole blood (sodium citrate anticoagulation) was collected from SD rats and centrifuged at 130 g for 10 minutes to obtain platelet-rich plasma (PRP). Platelet-poor plasma (PPP) was obtained by further centrifugation at 1500 g for 15 minutes. CLP-AM at a final concentration of 5 μg / ml was added to 200 μl PRP and gently mixed. After incubation for 30 minutes, AuNPs-PEG-Mal nanotraps were added and incubated for another 10 minutes. Subsequently, the ADP-induced platelet aggregation rate was measured.

[0127] The experimental results are as follows Fig.23As shown in the figure, the platelet aggregation rate results show that compared with the blank control group, CLP-AM can significantly reduce the platelet aggregation rate, and AuNPs-PEG-Mal nanotrap can significantly increase the platelet aggregation rate inhibited by CLP-AM. This shows that AuNPs-PEG-Mal nanotrap can effectively reverse the antiplatelet effect of clopidogrel.

[0128] Application Example 12 Tail tip bleeding time experiment

[0129] In this application example, the AuNPs-PEG-Mal nanotrap prepared in Example 5 was investigated for reversing the antiplatelet effect of clopidogrel, and the method was as follows: After a single injection of clopidogrel (2.5 mg / kg) into the tail vein of C57BL-6J mice, the AuNPs-PEG-Mal nanoparticle group was injected with 100 μl of AuNPs-PEG-Mal nanoparticles (100 nM) of Example 5, the CLP control group was injected with the same volume of saline, and the blank control group was not injected with clopidogrel, but only with saline. Subsequently, the bleeding time of the tail tip of the mice at different time points was measured, that is, the tail tip of the mice was quickly cut off by about 3 mm with sterile surgical scissors, and the tail was immediately immersed in 37°C saline. The tail tip bleeding time is from the continuous blood line seen in the saline to the blood line stopping and no repeated bleeding within 30 seconds.

[0130] The results are as follows Fig.24 As shown in the figure, after clopidogrel was intravenously injected into C57BL-6J mice, the tail tip bleeding time gradually increased, and the highest tail tip bleeding time gradually appeared, indicating that clopidogrel was gradually converted into clopidogrel active metabolites and exerted antiplatelet effects. The injection of AuNPs-PEG-Mal nano-traps significantly reduced the tail tip bleeding time caused by clopidogrel. This shows that AuNPs-PEG-Mal nano-traps have a significant functional reversal effect on the antiplatelet drug clopidogrel.

[0131] Application Example 13 Platelet Aggregation Experiment

[0132] In this application example, the PLGA-PEG-Mal nanotrap prepared in Example 6 was investigated for reversing the antiplatelet effect of clopidogrel in the ADP-induced platelet aggregation model, and the method was as follows: Anticoagulated whole blood (sodium citrate anticoagulation) was collected from SD rats and centrifuged at 130 g for 10 minutes to obtain platelet-rich plasma (PRP). Platelet-poor plasma (PPP) was obtained by further centrifugation at 1500 g for 15 minutes. CLP-AM at a final concentration of 6 μg / ml was added to 200 μl PRP and gently mixed. After incubation for 30 minutes, PLGA-PEG-Mal nanotraps were added and incubated for another 10 minutes. Subsequently, the ADP-induced platelet aggregation rate was measured using a CS2400 fully automated coagulation analyzer.

[0133] The experimental results are as follows Fig.25 As shown in the figure, the platelet aggregation rate results show that compared with the blank control group, CLP-AM can significantly reduce the platelet aggregation rate, and PLGA-PEG-Mal nano-traps can significantly increase the platelet aggregation rate inhibited by CLP-AM. That is, it shows that PLGA-PEG-Mal nano-traps can effectively reverse the antiplatelet effect of clopidogrel.

[0134] Application Example 14 Tail tip bleeding time experiment

[0135] In this application example, the PLGA-PEG-Mal nanotrap prepared in Example 6 was investigated for reversing the antiplatelet effect of clopidogrel, and the method was as follows: After a single injection of clopidogrel (3 mg / kg) into the tail vein of C57BL-6J mice, the PLGA-PEG-Mal nanoparticle group was injected with PLGA-PEG-Mal nanoparticles (2.5 mg / kg) of Example 6, the CLP control group was injected with the same volume of saline, and the blank control group was not injected with clopidogrel, but only with saline. Subsequently, the bleeding time of the tail tip of the mice at different time points was measured, that is, the tail tip of the mice was quickly cut off by about 3 mm with sterile surgical scissors, and the tail was immediately immersed in 37°C saline. The tail tip bleeding time is from the continuous blood line seen in the saline to the blood line stopping and no repeated bleeding within 30 seconds.

[0136] The results are as follows Fig.26 As shown in the figure, after clopidogrel was intravenously injected into C57BL-6J mice, the tail tip bleeding time gradually increased, and the highest tail tip bleeding time appeared at 3 hours, indicating that clopidogrel was gradually converted into clopidogrel active metabolites and exerted antiplatelet effects. The injection of PLGA-PEG-Mal nano-traps significantly reduced the tail tip bleeding time caused by clopidogrel. This shows that PLGA-PEG-Mal nano-traps have a significant functional reversal effect on the antiplatelet drug clopidogrel.

[0137] Application Example 15 Safety Experiment

[0138] In this application example, the safety test of the SiO2-Mal nanotrap prepared in Example 1 is investigated, and the method is as follows: The SiO2-Mal nano-traps (2.5 mg / kg) of Example 1 were injected into the tail vein of C57BL-6J mice once every 3 days for a total of 4 injections, and the control group was injected with the same volume of saline. Two days after the last treatment, the mice were euthanized and the main organs (heart, liver, spleen, lung, and kidney) were obtained for safety evaluation. The organs were preserved with 4% paraformaldehyde, embedded in paraffin, and stained with hematoxylin and eosin (H&E) to observe histological changes.

[0139] The results are as follows Fig. 27 As shown, the H&E staining results of the main organs of mice showed that the SiO2-Mal nanotrap had no adverse effects on the main organs of mice such as the heart, liver, spleen, lung, and kidney.

[0140] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A nano-capture agent, comprising a nano-carrier and a capture functional group modified inside or on the surface of the nano-carrier, wherein the capture functional group can undergo a rapid chemical reaction with a thienopyridine antiplatelet drug or its active metabolite to capture the antiplatelet drug or its metabolite.

2. The nano-capturing agent according to claim 1, characterized in that: The nanocarrier is selected from any one or a combination of at least two of silicon-based nanocarriers, lipid nanoparticles, gold nanoparticles, polymer nanocarriers, metal and oxide nanocarriers, metal-organic framework carriers, polypeptide nanoparticles, DNA / RNA nanocarriers, nanohydrogels, and carbon-based nanocarriers; And / or, the capture functional group is selected from any one or a combination of at least two of maleimide, o-benzoquinone, halogenated acetyl, and pyridine dithiol; wherein the halogenated acetyl can be iodoacetamide or chloroacetamide; And / or, the antiplatelet drug is one or more of clopidogrel, prasugrel, and ticlopidine.

3. The nano-capturing agent according to claim 2, characterized in that: The nanocarrier is mesoporous silicon nanoparticles, liposome nanoparticles, gold nanoparticles or polymer nanoparticles; preferably mesoporous silicon nanoparticles; And / or, the capture functional group is maleimide, o-benzoquinone or haloacetyl; preferably maleimide; And / or, the antiplatelet drug is selected from clopidogrel and prasugrel.

4. The nano-capturing agent according to claims 1-3, characterized in that: The nano-capturing agent is a nano-particle modified with a capturing group; its particle size is 1-5000nm, preferably 1-500nm, more preferably 10-200nm; its surface Zeta potential is -50mV to +50mV, preferably -50mV to +10mV.

5. The method for preparing the nano-capturing agent according to any one of claims 1 to 4, characterized in that: The method comprises the following steps: (1) preparing a nanocarrier; (2) modifying a capture group on the surface or inside of the nanocarrier; (3) collecting the nanocapture agent by centrifugation; Alternatively, the method comprises the following steps: (1) preparing a precursor molecule modified with a capture group; (2) preparing the precursor molecule to form nanoparticles; (3) collecting the nano-capture agent by centrifugation; When the nano-capturing agent of the present invention is a mesoporous silica capturing agent, firstly, silica nano-carrier particles with a mesoporous structure are prepared, and then the silane coupling agent modified with the capturing functional group is fixed into the mesoporous structure of the nano-carrier particles.

6. The method for preparing the nano-capturing agent according to claim 5, characterized in that: The silane coupling agent is silane polyethylene glycol maleimide Silane-PEG-MAL; Alternatively, the silane coupling agent is silane polyethylene glycol o-benzoquinone Silane-PEG-BQ; Alternatively, the silane coupling agent is silane polyethylene glycol iodoacetamide Silane-PEG-IA.

7. The method for preparing the nano-capturing agent according to claim 6, characterized in that: The molecular weight of the polyethylene glycol in the silane coupling agent is 400-20000, preferably 600, 800 or 1000.

8. The method for preparing the nano-capturing agent according to any one of claims 5 to 7, characterized in that: The method comprises the following steps: (1) preparing mesoporous silicon nanoparticles; (2) modifying a silane coupling agent modified with a maleimide group, an o-benzoquinone group, or a haloacetyl group into the mesopores of the mesoporous silicon nanoparticles; and (3) collecting the nano-capturing agent by centrifugation. The centrifugal speed is preferably 2000-20000g.

9. Use of the nano-capture agent according to any one of claims 1 to 4 or the preparation method according to any one of claims 5 to 8 in reversing the pharmacodynamic function of thienopyridine antiplatelet drugs or preventing bleeding caused by antiplatelet drugs.

10. Use of the nano-capture agent according to any one of claims 1 to 4 or the preparation method according to any one of claims 5 to 8 in the preparation of nano-drugs capable of reversing the pharmacodynamics of thienopyridine antiplatelet drugs or preventing bleeding caused by antiplatelet drugs.